Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Alberto F. Sobrero, MD, on Clinical Implications of Shorter-Duration CAPOX for Stage III Colon Cancer

Posted: Tuesday, June 9, 2020

Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses the findings of the IDEA study, which showed the efficacy of 3 months’ CAPOX for adjuvant treatment of stage III colon cancer. He also talks about whether there are some patients for whom a 6-month course should be considered.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement